Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Medicenna Therapeutics Corp

Healthcare CA MDNA

0.88CAD
0.02(2.33%)

Last update at 2026-03-10T20:00:00Z

Day Range

0.850.88
LowHigh

52 Week Range

0.781.97
LowHigh

Fundamentals

  • Previous Close 0.86
  • Market Cap68.40M
  • Volume55731
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.79800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -13.03000M -25.46600M -10.04800M -22.57700M -17.28900M
Minority interest - - - - -
Net income -11.80500M -25.46600M -10.04800M -22.64600M -17.39100M
Selling general administrative 5.91M 7.87M 6.99M 7.72M 6.49M
Selling and marketing expenses - 0.00500M - - -
Gross profit -0.05500M -0.00500M - - -
Reconciled depreciation 0.05M 0.00400M 0.00400M 0.04M 0.04M
Ebit -13.03000M -18.67500M -16.30300M -22.30000M -17.18700M
Ebitda -12.97500M -18.67000M -16.29800M -22.26200M -17.14700M
Depreciation and amortization 0.06M 0.00500M - 0.04M 0.04M
Non operating income net other - - - - -
Operating income -21.63100M -19.66300M -16.30300M -22.30000M -17.18700M
Other operating expenses 21.63M 19.66M - 22.47M 17.39M
Interest expense - - - 0.07M 0.00000M
Tax provision - - - - -
Interest income 8.60M 1.20M 6.25M 0.07M 0.11M
Net interest income 1.35M 1.20M 0.91M 0.07M 0.31M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.22500M - - 0.07M 0.10M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 21.58M 19.66M 16.30M 22.47M 17.39M
Cost of revenue 0.06M 0.00500M - - -
Total other income expense net 8.60M -5.80300M 5.34M -0.27700M -0.10200M
Discontinued operations - - - - -
Net income from continuing ops -11.80500M -25.46600M -10.04800M -22.57700M -17.28900M
Net income applicable to common shares -11.80500M -25.46600M -10.04800M -22.57700M -17.28900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 28.38M 19.13M 36.45M 23.46M 42.25M
Intangible assets 0.05M 0.06M 0.06M 0.07M 0.07M
Earning assets - - - - -
Other current assets - 0.93M - 1.55M -
Total liab 9.29M 13.94M 6.96M 2.62M 4.11M
Total stockholder equity 19.09M 5.19M 29.49M 20.84M 38.15M
Deferred long term liab - - - - -
Other current liab - 0.79M 3.16M 0.95M 1.83M
Common stock 116.30M 100.92M 100.92M 83.67M 79.59M
Capital stock 116.30M 100.92M 100.92M 83.67M 79.59M
Retained earnings -118.25200M -106.44700M -80.98100M -70.93300M -48.35600M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - - -
Cash 24.84M 16.98M 33.60M 20.54M 30.38M
Cash and equivalents 24.84M - 33.60M 20.54M 30.38M
Total current liabilities 4.43M 2.86M 6.96M 2.62M 4.11M
Current deferred revenue - - - - -
Net debt - -16.98200M - -20.53500M -30.34100M
Short term debt 0.00000M - 0.00000M 0.00000M 0.03M
Short long term debt - - - - -
Short long term debt total - - - - 0.03M
Other stockholder equity 0.00300M 10.70M 0.06M 7.93M 6.68M
Property plant equipment 0.16M - - 0.00000M 0.03M
Total current assets 28.17M 19.08M 36.38M 23.39M 42.15M
Long term investments - - - - -
Net tangible assets - - 29.43M 20.77M 38.07M
Short term investments - - - 0.00000M 10.01M
Net receivables - 1.16M 0.85M 1.31M 0.41M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.70M 2.07M 1.62M 1.67M 2.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.02M - 0.17M 0.23M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.21M 0.06M 0.06M 0.07M 0.10M
Capital lease obligations 0.17M - - 0.00000M 0.03M
Long term debt total 0.12M - 0.00000M 0.00000M 0.00000M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -0.03300M 0.00000M 0.00000M 10.05M 5.01M
Change to liabilities - - 1.18M -1.45200M 2.29M
Total cashflows from investing activities -0.03300M - 0.00000M 10.05M 5.01M
Net borrowings -0.01900M 0.00000M - -0.03700M -0.03900M
Total cash from financing activities 23.49M 0.00000M 24.76M 3.88M 18.26M
Change to operating activities - - - - -
Net income -11.80500M -25.46600M -10.04800M -22.57700M -17.28900M
Change in cash 7.86M -16.61400M 13.06M -9.84000M 7.68M
Begin period cash flow 16.98M 33.60M 20.54M 30.38M 22.70M
End period cash flow 24.84M 16.98M 33.60M 20.54M 30.38M
Total cash from operating activities -16.49200M -16.26000M -12.65700M -23.58400M -15.31100M
Issuance of capital stock 19.71M 0.00000M 24.76M 3.51M 11.41M
Depreciation 0.05M 0.00400M 0.00400M 0.04M 0.04M
Other cashflows from investing activities - - 0.00000M 10.05M 5.01M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.20900M 1.68M 1.23M -0.39200M -1.61200M
Sale purchase of stock 23.51M 0.00000M 24.76M 3.92M 18.30M
Other cashflows from financing activities 3.80M - - 0.41M 6.88M
Change to netincome - - -5.02300M 0.80M 1.26M
Capital expenditures 0.03M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.31M 0.74M 2.41M -1.84400M 0.68M
Stock based compensation 2.21M 1.21M 1.37M 1.42M 1.01M
Other non cash items -8.26800M 7.25M -0.97500M -0.61600M 0.25M
Free cash flow -16.52500M -16.26000M -12.65700M -23.58400M -15.31100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MDNA
Medicenna Therapeutics Corp		 0.02 2.33% 0.88 - 204.08 - 7.00 -6.1093
EPRX
Eupraxia Pharmaceuticals Inc		 0.21 1.97% 10.86 - - - 7.79 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -0.48 4.64% 9.87 - 11.59 9.31 57.98 6.52 20.27
MSCL
Satellos Bioscience Inc.		 -2.98 18.90% 12.79 4.81 - - 5.61 6.47
HBP
Helix BioPharma Corp.		 0.10 5.41% 1.95 - - - 8.70 -6.3589

Reports Covered

Stock Research & News

View All

Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Medicenna Therapeutics Corp

2 Bloor Street West, Toronto, ON, Canada, M4W 3E2

Key Executives

Name Title Year Born
Dr. Fahar Merchant Ph.D. Founder, Chairman, Pres & CEO 1957
Ms. Rosemina Merchant B.Sc., M.E.Sc Founder, Chief Devel. Officer & Director 1957
Ms. Elizabeth Williams C.A., CPA, CA, CPA CFO & Corp. Sec. 1978
Dr. Martin Bexon M.D., MBBS Acting Chief Medical Officer & Head of Clinical Devel. NA
Dr. Samuel R. Denmeade M.D. Scientific Advisor NA
Dr. Fahar Merchant Ph.D. Founder, Chairman, President & CEO 1957
Ms. Rosemina Merchant B.Sc., M.E.Sc Founder & Chief Development Officer 1957
Mr. David Hyman CA, CBV Chief Financial Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.